Skip to main contentSkip to navigationSkip to search

ICE 2026

Patient‑reported outcomes following CAM2029 treatment for patients with acromegaly in the Phase 3 ACROINNOVA 2 trial

Click the material you wish to view

ACROINNOVA 2-PRO

Pdf 0.5 MB

ACROINNOVA 2-PRO suppl

ZIP 1.2 MB

See all posters presented at
ICE 2026

Explore more

Disease areas

Camurus is committed to improving treatment outcomes and quality of life for people with severe and chronic diseases.

Congresses

Discover Camurus’ engagement at conducted and upcoming international medical conferences and events.